Remove Medical Schools Remove RNA Remove Trials
article thumbnail

Free webinar today: How is NGS informing oncology drug discovery?

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now. The post Free webinar today: How is NGS informing oncology drug discovery?

RNA 130
article thumbnail

Register now to learn how NGS is informing oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now.

RNA 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Webinar: Find out how NGS is informing oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now.

RNA 130
article thumbnail

Next-generation sequencing and oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now.

RNA 130
article thumbnail

How next-generation sequencing is informing oncology drug discovery

Drug Discovery World

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 130
article thumbnail

Revolutionary nanoparticles enable gene-editing in lungs

Drug Target Review

Scientists from the Massachusetts Institute of Technology (MIT) and the University of Massachusetts Medical School (UMass), US, have collaborated to create a novel type of nanoparticle that can deliver messenger RNA that encodes for beneficial proteins to the lungs.

RNA 98
article thumbnail

Personalised mRNA cancer vaccine prolongs survival in melanoma

Drug Discovery World

The clinical benefit was observed regardless of the tumour mutational burden (TMB) status, according to results from the Phase IIb KEYNOTE-942 clinical trial presented at the AACR Annual Meeting 2023, held April 14-19. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccine 130